{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:20:56Z","timestamp":1793917256754,"version":"4.8.0"},"reference-count":10,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T00:00:00Z","timestamp":1632873600000},"content-version":"vor","delay-in-days":40,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Nivolumab is an anti-programmed cell death protein 1 monoclonal antibody. While an effective treatment for a variety of tumors, immune checkpoint inhibitors (ICI) can cause immune-related adverse events such as ICI-pancreatic injury (ICI-PI). Here we present a case of a 60-year-old man with metastatic acral melanoma treated with nivolumab and ipilimumab who developed ICI-PI. Changes in positron emission tomography images preceded symptom onset. However, this case is unique in that the patient presented with cholestatic liver disease. Magnetic resonance cholangiopancreatography showed a dilated extrahepatic bile duct that resolved with steroid therapy, similar to the clinical course of autoimmune pancreatitis. ICI-PI has variable presentations including obstructive jaundice with a clinical course mimicking autoimmune pancreatitis and prompt awareness and treatment of ICI-PI is clinically significant given increasing use of ICIs.<\/jats:p>","DOI":"10.36401\/jipo-21-11","type":"journal-article","created":{"date-parts":[[2021,9,29]],"date-time":"2021-09-29T16:35:06Z","timestamp":1632933306000},"page":"208-211","source":"Crossref","is-referenced-by-count":5,"title":["Case Report: Nivolumab-Induced Autoimmune Pancreatitis"],"prefix":"10.36401","volume":"4","author":[{"given":"Preeya","family":"Goyal","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA, USA"},{"name":"Department of Internal Medicine, Division of Gastroenterology, Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin T.","family":"Moyers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA"},{"name":"Department of Internal Medicine, Division of Hematology and Oncology, Loma Linda University Medical Center, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bassem G.","family":"Elgohary","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad B.","family":"Hammami","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Gastroenterology, Loma Linda University Medical Center, Loma Linda, CA, USA"},{"name":"Department of Internal Medicine, Division of Gastroenterology, Veterans Affairs Loma Linda Healthcare System, Loma Linda, CA, USA"},{"name":"University of California, Riverside, Riverside, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","published-online":{"date-parts":[[2021,8,20]]},"reference":[{"key":"2021101219515454200_i2590-017X-4-4-208-b01","doi-asserted-by":"crossref","unstructured":"Yap\n              TA,\n            \n            \n              Parkes\n              EE,\n            \n            \n              Peng\n              W,\n            \n            et al.\n          \n          Development of immunotherapy combination strategies in cancer.\n\t\t\t\t\tCancer Discov.\n\t\t\t\t\t2021;\n\t\t\t\t\t11:\n\t\t\t\t\t1368\u2013\n\t\t\t\t\t1397.","DOI":"10.1158\/2159-8290.CD-20-1209"},{"key":"2021101219515454200_i2590-017X-4-4-208-b02","doi-asserted-by":"crossref","unstructured":"Weissman\n              S,\n            \n            \n              Aziz\n              M,\n            \n            \n              Perumapain\n              RB,\n            \n            et al.\n          \n          Ever-increasing diversity of drug-induced pancreatitis.\n\t\t\t\t\tWorld J Gastroenterol.\n\t\t\t\t\t2020;\n\t\t\t\t\t26:\n\t\t\t\t\t2902\u2013\n\t\t\t\t\t2915.","DOI":"10.3748\/wjg.v26.i22.2902"},{"key":"2021101219515454200_i2590-017X-4-4-208-b03","doi-asserted-by":"crossref","unstructured":"Shimosegawa\n              T,\n            \n            \n              Chari\n              S,\n            \n            \n              Frulloni\n              L,\n            \n            et al.\n          \n          International consensus diagnostic criteria for autoimmune pancreatitis.\n\t\t\t\t\tPancreas.\n\t\t\t\t\t2011;\n\t\t\t\t\t40:\n\t\t\t\t\t352\u2013\n\t\t\t\t\t358.","DOI":"10.1097\/MPA.0b013e3182142fd2"},{"key":"2021101219515454200_i2590-017X-4-4-208-b04","doi-asserted-by":"crossref","unstructured":"Naing\n              A,\n            \n            \n              Hajjar\n              J.\n            \n          \n          \n            Immunotherapy\n          .\n\t\t\t\t\t3rd ed.Springer Nature;\n\t\t\t\t\t2018.","DOI":"10.1007\/978-3-030-02505-2"},{"key":"2021101219515454200_i2590-017X-4-4-208-b05","doi-asserted-by":"crossref","unstructured":"Spain\n              L,\n            \n            \n              Diem\n              S,\n            \n            \n              Larkin\n              J.\n            \n          \n          Management of toxicities of immune checkpoint inhibitors.\n\t\t\t\t\tCancer Treat Rev.\n\t\t\t\t\t2016;\n\t\t\t\t\t44:\n\t\t\t\t\t51\u2013\n\t\t\t\t\t60.","DOI":"10.1016\/j.ctrv.2016.02.001"},{"key":"2021101219515454200_i2590-017X-4-4-208-b06","doi-asserted-by":"crossref","unstructured":"Su\n              Q,\n            \n            \n              Zhang\n              X-C,\n            \n            \n              Zhang\n              C-G,\n            \n            et al.\n          \n          Risk of immune-related pancreatitis in patients with solid tumors treated with immune checkpoint inhibitors: systematic assessment with meta-analysis.\n\t\t\t\t\tJ Immunol Res.\n\t\t\t\t\t2018;\n\t\t\t\t\t2018:\n\t\t\t\t\t1027323.","DOI":"10.1155\/2018\/1027323"},{"key":"2021101219515454200_i2590-017X-4-4-208-b07","doi-asserted-by":"crossref","unstructured":"Dehghani\n              L,\n            \n            \n              Mikail\n              N,\n            \n            \n              Kramkimel\n              N,\n            \n            et al.\n          \n          Autoimmune pancreatitis after nivolumab anti-programmed death receptor-1 treatment.\n\t\t\t\t\tEur J Cancer.\n\t\t\t\t\t2018;\n\t\t\t\t\t104:\n\t\t\t\t\t243\u2013\n\t\t\t\t\t246.","DOI":"10.1016\/j.ejca.2018.09.014"},{"key":"2021101219515454200_i2590-017X-4-4-208-b08","doi-asserted-by":"crossref","unstructured":"Nassri\n              AB,\n            \n            \n              Muenyi\n              V,\n            \n            \n              AlKhasawneh\n              A,\n            \n            et al.\n          \n          Ipilimumab and nivolumab induced steroid-refractory colitis treated with infliximab: a case report.\n\t\t\t\t\tWorld J Gastrointest Pharmacol Ther.\n\t\t\t\t\t2019;\n\t\t\t\t\t10:\n\t\t\t\t\t29\u2013\n\t\t\t\t\t34.","DOI":"10.4292\/wjgpt.v10.i1.29"},{"key":"2021101219515454200_i2590-017X-4-4-208-b09","doi-asserted-by":"crossref","unstructured":"Renon\n              J,\n            \n            \n              Mezquita\n              L,\n            \n            \n              Corral\n              J,\n            \n            et al.\n          \n          Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients.\n\t\t\t\t\tJ Thorac Dis.\n\t\t\t\t\t2018;\n\t\t\t\t\t10(Suppl 13):\n\t\t\t\t\tS1516\u2013\n\t\t\t\t\tS1533.","DOI":"10.21037\/jtd.2017.12.52"},{"key":"2021101219515454200_i2590-017X-4-4-208-b10","doi-asserted-by":"crossref","unstructured":"Pezzilli\n              R,\n            \n            \n              Pagano\n              N.\n            \n          \n          Pathophysiology of autoimmune pancreatitis.\n\t\t\t\t\tWorld J Gastrointest Pathophysiol.\n\t\t\t\t\t2014;\n\t\t\t\t\t5:\n\t\t\t\t\t11\u2013\n\t\t\t\t\t17.","DOI":"10.4291\/wjgp.v5.i1.11"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/4\/4\/208\/2927678\/i2590-017x-4-4-208.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/innovationsjournals-JIPO\/article-pdf\/4\/4\/208\/2927678\/i2590-017x-4-4-208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:48:17Z","timestamp":1765475297000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/4\/4\/article-p208.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,20]]},"references-count":10,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2021,8,20]]},"published-print":{"date-parts":[[2021,11,1]]}},"URL":"https:\/\/doi.org\/10.36401\/jipo-21-11","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,20]]}}}